Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea

202214 citationsJournal Articlebronze Open Access

Authors

Solriamfetol 300 mg/day significantly improved on-the-road driving performance in participants with EDS associated with OSA.

Good health and well-being

Published in: Human Psychopharmacology Clinical and Experimental

Volume 37, Issue 6, pp. e2845-e2845

Field-Weighted Citation Impact: 1.53